{"gene":"TRAM2","run_date":"2026-04-28T21:42:59","timeline":{"discoveries":[{"year":2004,"finding":"TRAM2 interacts with the ER Ca2+ pump SERCA2b via its C-terminal domain, and this interaction is required for type I collagen biosynthesis in hepatic stellate cells and fibroblasts. The C-terminal domain of TRAM2 interacts with SERCA2b as shown by yeast two-hybrid and co-immunoprecipitation; TRAM2 also co-precipitates with anti-collagen antibody. Deletion of the C-terminal domain inhibits collagen synthesis, and pharmacological inhibition of SERCA2b (thapsigargin) phenocopies this, inhibiting collagen triple helix folding and increasing intracellular degradation.","method":"Yeast two-hybrid, co-immunoprecipitation, deletion mutagenesis, pharmacological inhibition (thapsigargin), in vitro collagen folding assay","journal":"Molecular and cellular biology","confidence":"High","confidence_rationale":"Tier 1-2 — multiple orthogonal methods including yeast two-hybrid, reciprocal co-IP, mutagenesis, and functional assays in a single study","pmids":["14749390"],"is_preprint":false},{"year":2016,"finding":"TRAM2 controls regulated alternative translocation (RAT) of the transmembrane protein TM4SF20 by facilitating translocation of its first transmembrane helix into the ER lumen in the absence of ceramide. In the presence of ceramide, TM4SF20 translocation becomes TRAM2-independent, resulting in inversion of TM4SF20 membrane topology and stimulation of CREB3L1 cleavage.","method":"Genetic knockdown/knockout, topology assays, ceramide treatment, cell-based translocation assays","journal":"Molecular cell","confidence":"High","confidence_rationale":"Tier 2 — clean loss-of-function with defined molecular phenotype (topology inversion), replicated with pharmacological approach, mechanistic pathway established","pmids":["27499293"],"is_preprint":false},{"year":2021,"finding":"TRAM2 directly interacts with SERCA2b and modulates SERCA2b activity to couple calcium enrichment with collagen biosynthesis in osteoblasts, and TRAM2 silencing disrupts the calcium-collagen relationship and causes poor mineralization.","method":"Co-immunoprecipitation, siRNA silencing, biomineralization assays, calcium and collagen quantification","journal":"Advanced science","confidence":"Medium","confidence_rationale":"Tier 2-3 — co-IP and functional silencing with defined phenotype, consistent with prior foundational study","pmids":["34047068"],"is_preprint":false},{"year":2021,"finding":"TRAM2 and TRAM1 bind ceramide and its analogs, as identified by a photoactivatable and clickable short-chain ceramide probe (pac-C7-Cer). The ceramide-TRAM2 interaction is competed by naturally occurring long-chain ceramides, and binding of ceramide analogs to TRAM2 correlates with their ability to induce RAT of TM4SF20, providing mechanistic insight into ceramide sensing for regulated alternative translocation.","method":"Photoactivatable ceramide analog crosslinking, click chemistry, competition binding assay, RAT functional assay","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1-2 — chemical crosslinking probe with competition assay and functional correlation; mechanistic insight into ceramide binding by TRAM2","pmids":["34793833"],"is_preprint":false},{"year":2007,"finding":"Tram2 is a direct transcriptional target of Runx2 in osteoblasts, as identified by ChIP display. BMP-2-induced Runx2 expression coincides with increased Tram2 mRNA levels in multiple osteoblastic cell lines, and Runx2 overexpression in non-osteoblasts suppresses Tram2, which is alleviated by BMP-2 treatment.","method":"ChIP display, chromatin immunoprecipitation, BMP-2 treatment, quantitative RT-PCR across multiple cell lines","journal":"Journal of cellular biochemistry","confidence":"Medium","confidence_rationale":"Tier 2 — direct ChIP evidence for Runx2 occupancy at Tram2 locus plus functional mRNA regulation across multiple cell lines","pmids":["17486635"],"is_preprint":false},{"year":2021,"finding":"TRAM2 is transcriptionally activated by YAP/TEAD4 through an enhancer element (EnhancerTRAM2), and TRAM2 mediates YAP-induced cell proliferation, migration, and invasion. FSTL-1 was identified as a major direct client/secreted factor downstream of TRAM2 involved in these oncogenic phenotypes.","method":"Genome-wide ChIP profiling of YAP, CRISPR-based enhancer deletion screen, functional cell proliferation/migration/invasion assays, identification of FSTL-1 as TRAM2 downstream target","journal":"Genome biology","confidence":"Medium","confidence_rationale":"Tier 2 — ChIP + genetic enhancer deletion + functional assays with identified downstream effector","pmids":["33514403"],"is_preprint":false},{"year":2021,"finding":"miR-432-5p from iPSC-MSC exosomes suppresses TRAM2, which is described as a vital modulator of collagen biosynthesis in corneal stromal stem cells, reducing ECM deposition and scar formation.","method":"miRNA overexpression/knockdown, mRNA expression analysis, in vivo corneal model, target gene validation","journal":"Biomaterials","confidence":"Low","confidence_rationale":"Tier 3 — functional silencing with phenotypic readout but limited direct mechanistic validation of TRAM2's molecular role","pmids":["34923312"],"is_preprint":false},{"year":2018,"finding":"TRAM2 knockdown in oral squamous cell carcinoma cells inhibits cell migration, invasiveness, and transendothelial migration, with significant decreases in PERK and matrix metalloproteinases (MT1-MMP, MMP2, MMP9), suggesting TRAM2 controls cancer cell metastasis via regulation of ER stress signaling and MMP expression.","method":"siRNA knockdown, migration/invasion assays, Western blotting for PERK and MMPs","journal":"Journal of Cancer","confidence":"Low","confidence_rationale":"Tier 3 — single lab, single knockdown approach with downstream protein measurement but no direct mechanistic validation of TRAM2-PERK link","pmids":["30271493"],"is_preprint":false},{"year":2021,"finding":"TRAM2 silencing in glioma cells suppresses proliferation, invasion, migration, and EMT in vitro and inhibits tumorigenicity in vivo; TRAM2 is positively associated with activation of the PI3K/AKT/mTOR signaling pathway, and PI3K activator 740Y-P reverses the effects of TRAM2 silencing.","method":"siRNA silencing, in vitro proliferation/invasion/migration assays, xenograft in vivo model, PI3K activator rescue experiment, Western blotting of pathway components","journal":"Biochemical and biophysical research communications","confidence":"Low","confidence_rationale":"Tier 3 — epistasis-style rescue with PI3K activator is supportive but mechanism linking TRAM2 to PI3K/AKT/mTOR is not directly established","pmids":["34826698"],"is_preprint":false},{"year":2022,"finding":"RBM15B, transcriptionally activated by YY1, regulates TRAM2 mRNA stability in an m6A-dependent manner in hepatocellular carcinoma cells, establishing a YY1-RBM15B-TRAM2 regulatory axis.","method":"Co-IP, luciferase reporter assay, m6A methylation assay, siRNA knockdown, mRNA stability assay","journal":"Frontiers in oncology","confidence":"Low","confidence_rationale":"Tier 3 — mechanistic claim on m6A-dependent mRNA stability is plausible but validated in a single study with limited orthogonal confirmation","pmids":["35494016"],"is_preprint":false},{"year":2019,"finding":"Silencing of TRAM2 in human cells significantly reduces intracellular Staphylococcus aureus bacterial load and restores host cell viability; pharmacological inhibition of SERCA (thapsigargin), the TRAM2 interacting partner, also halts intracellular MRSA survival, suggesting TRAM2-SERCA coupling is required for intracellular bacterial infection.","method":"shRNA screen, siRNA silencing, thapsigargin pharmacological inhibition, bacterial load quantification","journal":"Scientific reports","confidence":"Low","confidence_rationale":"Tier 3 — functional screen finding with pharmacological corroboration, but direct molecular mechanism of TRAM2 in S. aureus infection not characterized","pmids":["31659191"],"is_preprint":false}],"current_model":"TRAM2 is an ER membrane protein and translocon component that physically interacts with the Ca2+ pump SERCA2b via its C-terminal domain to locally elevate Ca2+ concentration at sites of collagen synthesis, thereby facilitating collagen type I cotranslational insertion and triple-helix folding; additionally, TRAM2 acts as a ceramide-binding protein that controls regulated alternative translocation (RAT) of specific transmembrane proteins (e.g., TM4SF20) by directing the orientation of their first transmembrane helix during ER insertion, and TRAM2 expression is transcriptionally regulated by the Runx2/BMP-2 axis in osteoblasts and by YAP/TEAD4 through an enhancer in cancer cells."},"narrative":{"teleology":[{"year":2004,"claim":"Establishing that TRAM2 is not merely a translocon accessory but a functional bridge between ER calcium handling and collagen biosynthesis resolved how the ER coordinates Ca²⁺ supply with cotranslational folding of collagen.","evidence":"Yeast two-hybrid, reciprocal co-IP, C-terminal deletion mutagenesis, and thapsigargin treatment in hepatic stellate cells and fibroblasts","pmids":["14749390"],"confidence":"High","gaps":["Structural basis of the TRAM2–SERCA2b interface not resolved","Whether TRAM2 modulates SERCA2b enzymatic activity or merely tethers it to translocation sites was not distinguished","Generalizability to other ER-translocated substrates beyond type I collagen not tested"]},{"year":2007,"claim":"Identifying Tram2 as a direct Runx2 transcriptional target established how osteoblast differentiation programs upregulate the ER machinery needed for collagen production.","evidence":"ChIP display and chromatin immunoprecipitation for Runx2 occupancy at Tram2 locus; BMP-2-dependent mRNA induction across multiple osteoblastic cell lines","pmids":["17486635"],"confidence":"Medium","gaps":["Reporter-based validation of the Runx2-responsive element was not performed","Whether Runx2 regulation of TRAM2 is sufficient to drive collagen output was not tested"]},{"year":2016,"claim":"Demonstrating that TRAM2 controls topology of TM4SF20 during ER insertion revealed a new translocon function—regulated alternative translocation (RAT)—where ceramide switches a substrate from TRAM2-dependent to TRAM2-independent insertion.","evidence":"Genetic knockout/knockdown of TRAM2, topology assays, and ceramide treatment showing TM4SF20 transmembrane helix inversion and downstream CREB3L1 cleavage","pmids":["27499293"],"confidence":"High","gaps":["Whether TRAM2 directly contacts TM4SF20 during translocation or acts indirectly through translocon conformation was unresolved","Full repertoire of RAT substrates beyond TM4SF20 not defined"]},{"year":2021,"claim":"Showing that TRAM2 directly binds ceramide via photoactivatable probes provided the biochemical basis for how ceramide sensing at the translocon switches RAT substrate topology.","evidence":"Photoactivatable clickable ceramide crosslinking, competition by long-chain ceramides, and correlation with RAT functional readout","pmids":["34793833"],"confidence":"High","gaps":["Ceramide-binding site on TRAM2 not mapped at residue level","Whether ceramide binding alters TRAM2 conformation or displaces it from the translocon is unknown"]},{"year":2021,"claim":"Confirming the TRAM2–SERCA2b axis in osteoblasts and linking it to biomineralization extended the collagen-folding mechanism to skeletal tissue physiology.","evidence":"Co-IP, siRNA silencing, calcium quantification, and mineralization assays in osteoblast cultures","pmids":["34047068"],"confidence":"Medium","gaps":["In vivo skeletal phenotype of TRAM2 loss not characterized","Relative contribution of TRAM2-SERCA2b versus other ER calcium buffers to osteoblast collagen output not quantified"]},{"year":2021,"claim":"Identifying YAP/TEAD4 transcriptional control of TRAM2 through a specific enhancer, with FSTL-1 as a downstream secreted effector, connected TRAM2 to oncogenic signaling and explained its upregulation in aggressive cancers.","evidence":"Genome-wide YAP ChIP, CRISPR enhancer deletion, and functional proliferation/migration/invasion assays with FSTL-1 identification","pmids":["33514403"],"confidence":"Medium","gaps":["Whether TRAM2's oncogenic role depends on its translocon/SERCA2b functions or a distinct mechanism is unclear","FSTL-1 dependence on TRAM2-mediated translocation versus general secretory capacity not distinguished"]},{"year":null,"claim":"The structural basis of TRAM2's dual functionality—ceramide sensing for RAT and SERCA2b coupling for collagen folding—and whether these represent independent or coordinated mechanisms at the translocon remain undefined.","evidence":"","pmids":[],"confidence":"Low","gaps":["No high-resolution structure of TRAM2 or its complexes exists","Complete substrate repertoire for RAT is unknown","In vivo genetic models (knockout mice) have not been reported for TRAM2"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0008289","term_label":"lipid binding","supporting_discovery_ids":[3]},{"term_id":"GO:0098772","term_label":"molecular function regulator activity","supporting_discovery_ids":[0,1,2]}],"localization":[{"term_id":"GO:0005783","term_label":"endoplasmic reticulum","supporting_discovery_ids":[0,1,2,3]}],"pathway":[{"term_id":"R-HSA-392499","term_label":"Metabolism of proteins","supporting_discovery_ids":[0,1,2,3]}],"complexes":[],"partners":["SERCA2B","TM4SF20","TRAM1"],"other_free_text":[]},"mechanistic_narrative":"TRAM2 is an endoplasmic reticulum membrane protein that couples calcium homeostasis with protein translocation and collagen biosynthesis. Its C-terminal domain physically interacts with the ER Ca²⁺ pump SERCA2b, and this interaction is required for type I collagen triple-helix folding; disruption of TRAM2–SERCA2b coupling—by deletion mutagenesis or pharmacological SERCA inhibition—blocks collagen synthesis and mineralization in fibroblasts and osteoblasts [PMID:14749390, PMID:34047068]. TRAM2 also functions as a ceramide-binding translocon component that controls regulated alternative translocation (RAT): in the absence of ceramide, TRAM2 directs the first transmembrane helix of TM4SF20 into the ER lumen, whereas ceramide binding renders translocation TRAM2-independent, inverting TM4SF20 topology and activating CREB3L1 cleavage [PMID:27499293, PMID:34793833]. TRAM2 transcription is regulated by Runx2/BMP-2 in osteoblasts and by YAP/TEAD4 through a dedicated enhancer in cancer cells, linking its expression to both skeletal development and oncogenic signaling [PMID:17486635, PMID:33514403]."},"prefetch_data":{"uniprot":{"accession":"Q15035","full_name":"Translocating chain-associated membrane protein 2","aliases":[],"length_aa":370,"mass_kda":43.3,"function":"Necessary for collagen type I synthesis. May couple the activity of the ER Ca(2+) pump SERCA2B with the activity of the translocon. This coupling may increase the local Ca(2+) concentration at the site of collagen synthesis, and a high Ca(2+) concentration may be necessary for the function of molecular chaperones involved in collagen folding. Required for proper insertion of the first transmembrane helix N-terminus of TM4SF20 into the ER lumen, may act as a ceramide sensor for regulated alternative translocation (RAT) (PubMed:27499293)","subcellular_location":"Membrane","url":"https://www.uniprot.org/uniprotkb/Q15035/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/TRAM2","classification":"Not Classified","n_dependent_lines":8,"n_total_lines":1208,"dependency_fraction":0.006622516556291391},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/TRAM2","total_profiled":1310},"omim":[{"mim_id":"617505","title":"TRANSLOCATION-ASSOCIATED MEMBRANE PROTEIN 1-LIKE 1; TRAM1L1","url":"https://www.omim.org/entry/617505"},{"mim_id":"608485","title":"TRANSLOCATION-ASSOCIATED MEMBRANE PROTEIN 2; TRAM2","url":"https://www.omim.org/entry/608485"},{"mim_id":"108740","title":"ATPase, Ca(2+)-TRANSPORTING, SLOW-TWITCH; ATP2A2","url":"https://www.omim.org/entry/108740"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Approved","locations":[{"location":"Cytosol","reliability":"Approved"}],"tissue_specificity":"Low tissue specificity","tissue_distribution":"Detected in all","driving_tissues":[],"url":"https://www.proteinatlas.org/search/TRAM2"},"hgnc":{"alias_symbol":["KIAA0057"],"prev_symbol":[]},"alphafold":{"accession":"Q15035","domains":[{"cath_id":"-","chopping":"51-55_65-325","consensus_level":"medium","plddt":92.7194,"start":51,"end":325},{"cath_id":"1.20.5","chopping":"14-45","consensus_level":"medium","plddt":92.1381,"start":14,"end":45}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q15035","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q15035-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q15035-F1-predicted_aligned_error_v6.png","plddt_mean":85.75},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=TRAM2","jax_strain_url":"https://www.jax.org/strain/search?query=TRAM2"},"sequence":{"accession":"Q15035","fasta_url":"https://rest.uniprot.org/uniprotkb/Q15035.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q15035/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q15035"}},"corpus_meta":[{"pmid":"34923312","id":"PMC_34923312","title":"Exosomes-loaded thermosensitive hydrogels for corneal epithelium and stroma regeneration.","date":"2021","source":"Biomaterials","url":"https://pubmed.ncbi.nlm.nih.gov/34923312","citation_count":195,"is_preprint":false},{"pmid":"14623291","id":"PMC_14623291","title":"Identification of a novel adrenomedullin gene family in teleost fish.","date":"2003","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/14623291","citation_count":71,"is_preprint":false},{"pmid":"14749390","id":"PMC_14749390","title":"TRAM2 protein interacts with endoplasmic reticulum Ca2+ pump Serca2b and is necessary for collagen type I synthesis.","date":"2004","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/14749390","citation_count":67,"is_preprint":false},{"pmid":"27499293","id":"PMC_27499293","title":"Inverting the Topology of a Transmembrane Protein by Regulating the Translocation of the First Transmembrane Helix.","date":"2016","source":"Molecular cell","url":"https://pubmed.ncbi.nlm.nih.gov/27499293","citation_count":37,"is_preprint":false},{"pmid":"25148458","id":"PMC_25148458","title":"Aromatase inhibitor-associated bone fractures: a case-cohort GWAS and functional genomics.","date":"2014","source":"Molecular endocrinology (Baltimore, Md.)","url":"https://pubmed.ncbi.nlm.nih.gov/25148458","citation_count":37,"is_preprint":false},{"pmid":"18252063","id":"PMC_18252063","title":"Preimplantation genetic diagnosis for autosomal recessive polycystic kidney disease.","date":"2008","source":"Reproductive biomedicine online","url":"https://pubmed.ncbi.nlm.nih.gov/18252063","citation_count":31,"is_preprint":false},{"pmid":"35494016","id":"PMC_35494016","title":"YY1-Targeted RBM15B Promotes Hepatocellular Carcinoma Cell Proliferation and Sorafenib Resistance by Promoting TRAM2 Expression in an m6A-Dependent Manner.","date":"2022","source":"Frontiers in oncology","url":"https://pubmed.ncbi.nlm.nih.gov/35494016","citation_count":24,"is_preprint":false},{"pmid":"34047068","id":"PMC_34047068","title":"Calcium-Collagen Coupling is Vital for Biomineralization Schedule.","date":"2021","source":"Advanced science (Weinheim, Baden-Wurttemberg, Germany)","url":"https://pubmed.ncbi.nlm.nih.gov/34047068","citation_count":23,"is_preprint":false},{"pmid":"30271493","id":"PMC_30271493","title":"Overexpression of Translocation Associated Membrane Protein 2 Leading to Cancer-Associated Matrix Metalloproteinase Activation as a Putative Metastatic Factor for Human Oral Cancer.","date":"2018","source":"Journal of Cancer","url":"https://pubmed.ncbi.nlm.nih.gov/30271493","citation_count":22,"is_preprint":false},{"pmid":"29439661","id":"PMC_29439661","title":"Genome-wide scan for commons SNPs affecting bovine leukemia virus infection level in dairy cattle.","date":"2018","source":"BMC genomics","url":"https://pubmed.ncbi.nlm.nih.gov/29439661","citation_count":20,"is_preprint":false},{"pmid":"33514403","id":"PMC_33514403","title":"A comprehensive enhancer screen identifies TRAM2 as a key and novel mediator of YAP oncogenesis.","date":"2021","source":"Genome biology","url":"https://pubmed.ncbi.nlm.nih.gov/33514403","citation_count":19,"is_preprint":false},{"pmid":"17486635","id":"PMC_17486635","title":"Identification of novel Runx2 targets in osteoblasts: cell type-specific BMP-dependent regulation of Tram2.","date":"2007","source":"Journal of cellular biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/17486635","citation_count":18,"is_preprint":false},{"pmid":"19041736","id":"PMC_19041736","title":"Three de novo losses and one insertion within a pericentric inversion of chromosome 6 in a patient with complete absence of expressive speech and reduced pain perception.","date":"2008","source":"European journal of medical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/19041736","citation_count":17,"is_preprint":false},{"pmid":"34826698","id":"PMC_34826698","title":"TRAM2 promotes the malignant progression of glioma through PI3K/AKT/mTOR pathway.","date":"2021","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/34826698","citation_count":16,"is_preprint":false},{"pmid":"32856532","id":"PMC_32856532","title":"Anti-cyclic citrullinated peptide antibodies are associated with radiographic damage but not disease activity in early rheumatoid arthritis diagnosed in 2006-2011.","date":"2020","source":"Scandinavian journal of rheumatology","url":"https://pubmed.ncbi.nlm.nih.gov/32856532","citation_count":16,"is_preprint":false},{"pmid":"37041422","id":"PMC_37041422","title":"Downregulation of circ-STK39 suppresses pancreatic cancer progression by sponging mir-140-3p and regulating TRAM2-mediated epithelial-mesenchymal transition.","date":"2023","source":"Apoptosis : an international journal on programmed cell death","url":"https://pubmed.ncbi.nlm.nih.gov/37041422","citation_count":12,"is_preprint":false},{"pmid":"16547030","id":"PMC_16547030","title":"Dual control of quorum sensing by two TraM-type antiactivators in Agrobacterium tumefaciens octopine strain A6.","date":"2006","source":"Journal of bacteriology","url":"https://pubmed.ncbi.nlm.nih.gov/16547030","citation_count":12,"is_preprint":false},{"pmid":"16997969","id":"PMC_16997969","title":"Crystal structure and mechanism of TraM2, a second quorum-sensing antiactivator of Agrobacterium tumefaciens strain A6.","date":"2006","source":"Journal of bacteriology","url":"https://pubmed.ncbi.nlm.nih.gov/16997969","citation_count":11,"is_preprint":false},{"pmid":"16876319","id":"PMC_16876319","title":"Mutation analyses of genes on 6p12-p11 in patients with juvenile myoclonic epilepsy.","date":"2006","source":"Neuroscience letters","url":"https://pubmed.ncbi.nlm.nih.gov/16876319","citation_count":11,"is_preprint":false},{"pmid":"34793833","id":"PMC_34793833","title":"Identification of TRAMs as sphingolipid-binding proteins using a photoactivatable and clickable short-chain ceramide analog.","date":"2021","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/34793833","citation_count":10,"is_preprint":false},{"pmid":"31659191","id":"PMC_31659191","title":"Identification of novel targets for host-directed therapeutics against intracellular Staphylococcus aureus.","date":"2019","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/31659191","citation_count":10,"is_preprint":false},{"pmid":"12200217","id":"PMC_12200217","title":"Identification and mutational analysis of candidate genes for juvenile myoclonic epilepsy on 6p11-p12: LRRC1, GCLC, KIAA0057 and CLIC5.","date":"2002","source":"Epilepsy research","url":"https://pubmed.ncbi.nlm.nih.gov/12200217","citation_count":9,"is_preprint":false},{"pmid":"34700098","id":"PMC_34700098","title":"A comparative study of libido in drakes: from phenotypes to molecules.","date":"2021","source":"Poultry science","url":"https://pubmed.ncbi.nlm.nih.gov/34700098","citation_count":9,"is_preprint":false},{"pmid":"24464459","id":"PMC_24464459","title":"Identification and characterization of a second quorum-sensing system in Agrobacterium tumefaciens A6.","date":"2014","source":"Journal of bacteriology","url":"https://pubmed.ncbi.nlm.nih.gov/24464459","citation_count":8,"is_preprint":false},{"pmid":"33057364","id":"PMC_33057364","title":"Genes regulating membrane-associated E-cadherin and proliferation in adenomatous polyposis coli mutant colon cancer cells: High content siRNA screen.","date":"2020","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/33057364","citation_count":5,"is_preprint":false},{"pmid":"34462884","id":"PMC_34462884","title":"Identification of Four Enhancer-Associated Genes as Risk Signature for Diffuse Glioma Patients.","date":"2021","source":"Journal of molecular neuroscience : MN","url":"https://pubmed.ncbi.nlm.nih.gov/34462884","citation_count":2,"is_preprint":false},{"pmid":"41858239","id":"PMC_41858239","title":"Molecular Subtype Classification and Mechanistic Investigation Based on Ferroptosis-Related lncRNAs in Ovarian Cancer.","date":"2026","source":"Genetics research","url":"https://pubmed.ncbi.nlm.nih.gov/41858239","citation_count":0,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":14760,"output_tokens":2771,"usd":0.042923},"stage2":{"model":"claude-opus-4-6","input_tokens":6096,"output_tokens":4018,"usd":0.196395},"total_usd":0.239318,"stage1_batch_id":"msgbatch_01RPbVc9PDH9zQmYK5Hs6srm","stage2_batch_id":"msgbatch_01JVbVLzeKN2yVrsGp3zC8aM","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2004,\n      \"finding\": \"TRAM2 interacts with the ER Ca2+ pump SERCA2b via its C-terminal domain, and this interaction is required for type I collagen biosynthesis in hepatic stellate cells and fibroblasts. The C-terminal domain of TRAM2 interacts with SERCA2b as shown by yeast two-hybrid and co-immunoprecipitation; TRAM2 also co-precipitates with anti-collagen antibody. Deletion of the C-terminal domain inhibits collagen synthesis, and pharmacological inhibition of SERCA2b (thapsigargin) phenocopies this, inhibiting collagen triple helix folding and increasing intracellular degradation.\",\n      \"method\": \"Yeast two-hybrid, co-immunoprecipitation, deletion mutagenesis, pharmacological inhibition (thapsigargin), in vitro collagen folding assay\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — multiple orthogonal methods including yeast two-hybrid, reciprocal co-IP, mutagenesis, and functional assays in a single study\",\n      \"pmids\": [\"14749390\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"TRAM2 controls regulated alternative translocation (RAT) of the transmembrane protein TM4SF20 by facilitating translocation of its first transmembrane helix into the ER lumen in the absence of ceramide. In the presence of ceramide, TM4SF20 translocation becomes TRAM2-independent, resulting in inversion of TM4SF20 membrane topology and stimulation of CREB3L1 cleavage.\",\n      \"method\": \"Genetic knockdown/knockout, topology assays, ceramide treatment, cell-based translocation assays\",\n      \"journal\": \"Molecular cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — clean loss-of-function with defined molecular phenotype (topology inversion), replicated with pharmacological approach, mechanistic pathway established\",\n      \"pmids\": [\"27499293\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"TRAM2 directly interacts with SERCA2b and modulates SERCA2b activity to couple calcium enrichment with collagen biosynthesis in osteoblasts, and TRAM2 silencing disrupts the calcium-collagen relationship and causes poor mineralization.\",\n      \"method\": \"Co-immunoprecipitation, siRNA silencing, biomineralization assays, calcium and collagen quantification\",\n      \"journal\": \"Advanced science\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 — co-IP and functional silencing with defined phenotype, consistent with prior foundational study\",\n      \"pmids\": [\"34047068\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"TRAM2 and TRAM1 bind ceramide and its analogs, as identified by a photoactivatable and clickable short-chain ceramide probe (pac-C7-Cer). The ceramide-TRAM2 interaction is competed by naturally occurring long-chain ceramides, and binding of ceramide analogs to TRAM2 correlates with their ability to induce RAT of TM4SF20, providing mechanistic insight into ceramide sensing for regulated alternative translocation.\",\n      \"method\": \"Photoactivatable ceramide analog crosslinking, click chemistry, competition binding assay, RAT functional assay\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — chemical crosslinking probe with competition assay and functional correlation; mechanistic insight into ceramide binding by TRAM2\",\n      \"pmids\": [\"34793833\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"Tram2 is a direct transcriptional target of Runx2 in osteoblasts, as identified by ChIP display. BMP-2-induced Runx2 expression coincides with increased Tram2 mRNA levels in multiple osteoblastic cell lines, and Runx2 overexpression in non-osteoblasts suppresses Tram2, which is alleviated by BMP-2 treatment.\",\n      \"method\": \"ChIP display, chromatin immunoprecipitation, BMP-2 treatment, quantitative RT-PCR across multiple cell lines\",\n      \"journal\": \"Journal of cellular biochemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — direct ChIP evidence for Runx2 occupancy at Tram2 locus plus functional mRNA regulation across multiple cell lines\",\n      \"pmids\": [\"17486635\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"TRAM2 is transcriptionally activated by YAP/TEAD4 through an enhancer element (EnhancerTRAM2), and TRAM2 mediates YAP-induced cell proliferation, migration, and invasion. FSTL-1 was identified as a major direct client/secreted factor downstream of TRAM2 involved in these oncogenic phenotypes.\",\n      \"method\": \"Genome-wide ChIP profiling of YAP, CRISPR-based enhancer deletion screen, functional cell proliferation/migration/invasion assays, identification of FSTL-1 as TRAM2 downstream target\",\n      \"journal\": \"Genome biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — ChIP + genetic enhancer deletion + functional assays with identified downstream effector\",\n      \"pmids\": [\"33514403\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"miR-432-5p from iPSC-MSC exosomes suppresses TRAM2, which is described as a vital modulator of collagen biosynthesis in corneal stromal stem cells, reducing ECM deposition and scar formation.\",\n      \"method\": \"miRNA overexpression/knockdown, mRNA expression analysis, in vivo corneal model, target gene validation\",\n      \"journal\": \"Biomaterials\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 — functional silencing with phenotypic readout but limited direct mechanistic validation of TRAM2's molecular role\",\n      \"pmids\": [\"34923312\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"TRAM2 knockdown in oral squamous cell carcinoma cells inhibits cell migration, invasiveness, and transendothelial migration, with significant decreases in PERK and matrix metalloproteinases (MT1-MMP, MMP2, MMP9), suggesting TRAM2 controls cancer cell metastasis via regulation of ER stress signaling and MMP expression.\",\n      \"method\": \"siRNA knockdown, migration/invasion assays, Western blotting for PERK and MMPs\",\n      \"journal\": \"Journal of Cancer\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 — single lab, single knockdown approach with downstream protein measurement but no direct mechanistic validation of TRAM2-PERK link\",\n      \"pmids\": [\"30271493\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"TRAM2 silencing in glioma cells suppresses proliferation, invasion, migration, and EMT in vitro and inhibits tumorigenicity in vivo; TRAM2 is positively associated with activation of the PI3K/AKT/mTOR signaling pathway, and PI3K activator 740Y-P reverses the effects of TRAM2 silencing.\",\n      \"method\": \"siRNA silencing, in vitro proliferation/invasion/migration assays, xenograft in vivo model, PI3K activator rescue experiment, Western blotting of pathway components\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 — epistasis-style rescue with PI3K activator is supportive but mechanism linking TRAM2 to PI3K/AKT/mTOR is not directly established\",\n      \"pmids\": [\"34826698\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"RBM15B, transcriptionally activated by YY1, regulates TRAM2 mRNA stability in an m6A-dependent manner in hepatocellular carcinoma cells, establishing a YY1-RBM15B-TRAM2 regulatory axis.\",\n      \"method\": \"Co-IP, luciferase reporter assay, m6A methylation assay, siRNA knockdown, mRNA stability assay\",\n      \"journal\": \"Frontiers in oncology\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 — mechanistic claim on m6A-dependent mRNA stability is plausible but validated in a single study with limited orthogonal confirmation\",\n      \"pmids\": [\"35494016\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"Silencing of TRAM2 in human cells significantly reduces intracellular Staphylococcus aureus bacterial load and restores host cell viability; pharmacological inhibition of SERCA (thapsigargin), the TRAM2 interacting partner, also halts intracellular MRSA survival, suggesting TRAM2-SERCA coupling is required for intracellular bacterial infection.\",\n      \"method\": \"shRNA screen, siRNA silencing, thapsigargin pharmacological inhibition, bacterial load quantification\",\n      \"journal\": \"Scientific reports\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 — functional screen finding with pharmacological corroboration, but direct molecular mechanism of TRAM2 in S. aureus infection not characterized\",\n      \"pmids\": [\"31659191\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"TRAM2 is an ER membrane protein and translocon component that physically interacts with the Ca2+ pump SERCA2b via its C-terminal domain to locally elevate Ca2+ concentration at sites of collagen synthesis, thereby facilitating collagen type I cotranslational insertion and triple-helix folding; additionally, TRAM2 acts as a ceramide-binding protein that controls regulated alternative translocation (RAT) of specific transmembrane proteins (e.g., TM4SF20) by directing the orientation of their first transmembrane helix during ER insertion, and TRAM2 expression is transcriptionally regulated by the Runx2/BMP-2 axis in osteoblasts and by YAP/TEAD4 through an enhancer in cancer cells.\"\n}\n```","stage2_raw":"```json\n{\n  \"mechanistic_narrative\": \"TRAM2 is an endoplasmic reticulum membrane protein that couples calcium homeostasis with protein translocation and collagen biosynthesis. Its C-terminal domain physically interacts with the ER Ca²⁺ pump SERCA2b, and this interaction is required for type I collagen triple-helix folding; disruption of TRAM2–SERCA2b coupling—by deletion mutagenesis or pharmacological SERCA inhibition—blocks collagen synthesis and mineralization in fibroblasts and osteoblasts [PMID:14749390, PMID:34047068]. TRAM2 also functions as a ceramide-binding translocon component that controls regulated alternative translocation (RAT): in the absence of ceramide, TRAM2 directs the first transmembrane helix of TM4SF20 into the ER lumen, whereas ceramide binding renders translocation TRAM2-independent, inverting TM4SF20 topology and activating CREB3L1 cleavage [PMID:27499293, PMID:34793833]. TRAM2 transcription is regulated by Runx2/BMP-2 in osteoblasts and by YAP/TEAD4 through a dedicated enhancer in cancer cells, linking its expression to both skeletal development and oncogenic signaling [PMID:17486635, PMID:33514403].\",\n  \"teleology\": [\n    {\n      \"year\": 2004,\n      \"claim\": \"Establishing that TRAM2 is not merely a translocon accessory but a functional bridge between ER calcium handling and collagen biosynthesis resolved how the ER coordinates Ca²⁺ supply with cotranslational folding of collagen.\",\n      \"evidence\": \"Yeast two-hybrid, reciprocal co-IP, C-terminal deletion mutagenesis, and thapsigargin treatment in hepatic stellate cells and fibroblasts\",\n      \"pmids\": [\"14749390\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"Structural basis of the TRAM2–SERCA2b interface not resolved\",\n        \"Whether TRAM2 modulates SERCA2b enzymatic activity or merely tethers it to translocation sites was not distinguished\",\n        \"Generalizability to other ER-translocated substrates beyond type I collagen not tested\"\n      ]\n    },\n    {\n      \"year\": 2007,\n      \"claim\": \"Identifying Tram2 as a direct Runx2 transcriptional target established how osteoblast differentiation programs upregulate the ER machinery needed for collagen production.\",\n      \"evidence\": \"ChIP display and chromatin immunoprecipitation for Runx2 occupancy at Tram2 locus; BMP-2-dependent mRNA induction across multiple osteoblastic cell lines\",\n      \"pmids\": [\"17486635\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"Reporter-based validation of the Runx2-responsive element was not performed\",\n        \"Whether Runx2 regulation of TRAM2 is sufficient to drive collagen output was not tested\"\n      ]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Demonstrating that TRAM2 controls topology of TM4SF20 during ER insertion revealed a new translocon function—regulated alternative translocation (RAT)—where ceramide switches a substrate from TRAM2-dependent to TRAM2-independent insertion.\",\n      \"evidence\": \"Genetic knockout/knockdown of TRAM2, topology assays, and ceramide treatment showing TM4SF20 transmembrane helix inversion and downstream CREB3L1 cleavage\",\n      \"pmids\": [\"27499293\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"Whether TRAM2 directly contacts TM4SF20 during translocation or acts indirectly through translocon conformation was unresolved\",\n        \"Full repertoire of RAT substrates beyond TM4SF20 not defined\"\n      ]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Showing that TRAM2 directly binds ceramide via photoactivatable probes provided the biochemical basis for how ceramide sensing at the translocon switches RAT substrate topology.\",\n      \"evidence\": \"Photoactivatable clickable ceramide crosslinking, competition by long-chain ceramides, and correlation with RAT functional readout\",\n      \"pmids\": [\"34793833\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"Ceramide-binding site on TRAM2 not mapped at residue level\",\n        \"Whether ceramide binding alters TRAM2 conformation or displaces it from the translocon is unknown\"\n      ]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Confirming the TRAM2–SERCA2b axis in osteoblasts and linking it to biomineralization extended the collagen-folding mechanism to skeletal tissue physiology.\",\n      \"evidence\": \"Co-IP, siRNA silencing, calcium quantification, and mineralization assays in osteoblast cultures\",\n      \"pmids\": [\"34047068\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"In vivo skeletal phenotype of TRAM2 loss not characterized\",\n        \"Relative contribution of TRAM2-SERCA2b versus other ER calcium buffers to osteoblast collagen output not quantified\"\n      ]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Identifying YAP/TEAD4 transcriptional control of TRAM2 through a specific enhancer, with FSTL-1 as a downstream secreted effector, connected TRAM2 to oncogenic signaling and explained its upregulation in aggressive cancers.\",\n      \"evidence\": \"Genome-wide YAP ChIP, CRISPR enhancer deletion, and functional proliferation/migration/invasion assays with FSTL-1 identification\",\n      \"pmids\": [\"33514403\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"Whether TRAM2's oncogenic role depends on its translocon/SERCA2b functions or a distinct mechanism is unclear\",\n        \"FSTL-1 dependence on TRAM2-mediated translocation versus general secretory capacity not distinguished\"\n      ]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"The structural basis of TRAM2's dual functionality—ceramide sensing for RAT and SERCA2b coupling for collagen folding—and whether these represent independent or coordinated mechanisms at the translocon remain undefined.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\n        \"No high-resolution structure of TRAM2 or its complexes exists\",\n        \"Complete substrate repertoire for RAT is unknown\",\n        \"In vivo genetic models (knockout mice) have not been reported for TRAM2\"\n      ]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0008289\", \"supporting_discovery_ids\": [3]},\n      {\"term_id\": \"GO:0098772\", \"supporting_discovery_ids\": [0, 1, 2]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005783\", \"supporting_discovery_ids\": [0, 1, 2, 3]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"GO:0009609507\", \"supporting_discovery_ids\": [1, 3]},\n      {\"term_id\": \"R-HSA-392499\", \"supporting_discovery_ids\": [0, 1, 2, 3]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\"SERCA2b\", \"TM4SF20\", \"TRAM1\"],\n    \"other_free_text\": []\n  }\n}\n```\n\nWait, I need to fix the pathway term_id. Let me correct — `GO:0009609507` is not valid. The correct Reactome pathway ID for Protein localization is `R-HSA-9609507`. Let me also reconsider whether TRAM1 qualifies as a direct physical partner — it was identified alongside TRAM2 as a ceramide binder but not shown as a direct physical interactor of TRAM2.\n\n```json\n{\n  \"mechanistic_narrative\": \"TRAM2 is an endoplasmic reticulum membrane protein that couples calcium homeostasis with protein translocation and collagen biosynthesis. Its C-terminal domain physically interacts with the ER Ca²⁺ pump SERCA2b, and this interaction is required for type I collagen triple-helix folding; disruption of TRAM2–SERCA2b coupling—by deletion mutagenesis or pharmacological SERCA inhibition—blocks collagen synthesis and mineralization in fibroblasts and osteoblasts [PMID:14749390, PMID:34047068]. TRAM2 also functions as a ceramide-binding translocon component that controls regulated alternative translocation (RAT): in the absence of ceramide, TRAM2 directs the first transmembrane helix of TM4SF20 into the ER lumen, whereas ceramide binding renders translocation TRAM2-independent, inverting TM4SF20 topology and activating CREB3L1 cleavage [PMID:27499293, PMID:34793833]. TRAM2 transcription is regulated by Runx2/BMP-2 in osteoblasts and by YAP/TEAD4 through a dedicated enhancer in cancer cells, linking its expression to both skeletal development and oncogenic signaling [PMID:17486635, PMID:33514403].\",\n  \"teleology\": [\n    {\n      \"year\": 2004,\n      \"claim\": \"Establishing that TRAM2 is not merely a translocon accessory but a functional bridge between ER calcium handling and collagen biosynthesis resolved how the ER coordinates Ca²⁺ supply with cotranslational folding of collagen.\",\n      \"evidence\": \"Yeast two-hybrid, reciprocal co-IP, C-terminal deletion mutagenesis, and thapsigargin treatment in hepatic stellate cells and fibroblasts\",\n      \"pmids\": [\"14749390\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"Structural basis of the TRAM2–SERCA2b interface not resolved\",\n        \"Whether TRAM2 modulates SERCA2b enzymatic activity or merely tethers it to translocation sites was not distinguished\",\n        \"Generalizability to other ER-translocated substrates beyond type I collagen not tested\"\n      ]\n    },\n    {\n      \"year\": 2007,\n      \"claim\": \"Identifying Tram2 as a direct Runx2 transcriptional target established how osteoblast differentiation programs upregulate the ER machinery needed for collagen production.\",\n      \"evidence\": \"ChIP display and chromatin immunoprecipitation for Runx2 occupancy at Tram2 locus; BMP-2-dependent mRNA induction across multiple osteoblastic cell lines\",\n      \"pmids\": [\"17486635\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"Reporter-based validation of the Runx2-responsive element was not performed\",\n        \"Whether Runx2 regulation of TRAM2 is sufficient to drive collagen output was not tested\"\n      ]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Demonstrating that TRAM2 controls topology of TM4SF20 during ER insertion revealed a new translocon function—regulated alternative translocation (RAT)—where ceramide switches a substrate from TRAM2-dependent to TRAM2-independent insertion.\",\n      \"evidence\": \"Genetic knockout/knockdown of TRAM2, topology assays, and ceramide treatment showing TM4SF20 transmembrane helix inversion and downstream CREB3L1 cleavage\",\n      \"pmids\": [\"27499293\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"Whether TRAM2 directly contacts TM4SF20 during translocation or acts indirectly through translocon conformation was unresolved\",\n        \"Full repertoire of RAT substrates beyond TM4SF20 not defined\"\n      ]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Showing that TRAM2 directly binds ceramide via photoactivatable probes provided the biochemical basis for how ceramide sensing at the translocon switches RAT substrate topology.\",\n      \"evidence\": \"Photoactivatable clickable ceramide crosslinking, competition by long-chain ceramides, and correlation with RAT functional readout\",\n      \"pmids\": [\"34793833\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"Ceramide-binding site on TRAM2 not mapped at residue level\",\n        \"Whether ceramide binding alters TRAM2 conformation or displaces it from the translocon is unknown\"\n      ]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Confirming the TRAM2–SERCA2b axis in osteoblasts and linking it to biomineralization extended the collagen-folding mechanism to skeletal tissue physiology.\",\n      \"evidence\": \"Co-IP, siRNA silencing, calcium quantification, and mineralization assays in osteoblast cultures\",\n      \"pmids\": [\"34047068\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"In vivo skeletal phenotype of TRAM2 loss not characterized\",\n        \"Relative contribution of TRAM2-SERCA2b versus other ER calcium buffers to osteoblast collagen output not quantified\"\n      ]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Identifying YAP/TEAD4 transcriptional control of TRAM2 through a specific enhancer, with FSTL-1 as a downstream secreted effector, connected TRAM2 to oncogenic signaling and explained its upregulation in aggressive cancers.\",\n      \"evidence\": \"Genome-wide YAP ChIP, CRISPR enhancer deletion, and functional proliferation/migration/invasion assays with FSTL-1 identification\",\n      \"pmids\": [\"33514403\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"Whether TRAM2's oncogenic role depends on its translocon/SERCA2b functions or a distinct mechanism is unclear\",\n        \"FSTL-1 dependence on TRAM2-mediated translocation versus general secretory capacity not distinguished\"\n      ]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"The structural basis of TRAM2's dual functionality—ceramide sensing for RAT and SERCA2b coupling for collagen folding—and whether these represent independent or coordinated mechanisms at the translocon remain undefined.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\n        \"No high-resolution structure of TRAM2 or its complexes exists\",\n        \"Complete substrate repertoire for RAT is unknown\",\n        \"In vivo genetic models (knockout mice) have not been reported for TRAM2\"\n      ]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0008289\", \"supporting_discovery_ids\": [3]},\n      {\"term_id\": \"GO:0098772\", \"supporting_discovery_ids\": [0, 1, 2]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005783\", \"supporting_discovery_ids\": [0, 1, 2, 3]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-9609507\", \"supporting_discovery_ids\": [1, 3]},\n      {\"term_id\": \"R-HSA-392499\", \"supporting_discovery_ids\": [0, 1, 2, 3]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\"SERCA2b\", \"TM4SF20\"],\n    \"other_free_text\": []\n  }\n}\n```"}